Project Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Open label risperidone in children and adolescents with autistic disorder  

Although behavioral and educational therapies and a variety of medications may help manage some symptoms of autism, there are no FDA-approved treatments for the disorder. However, atypical antipsychotics have emerged as promising therapies for the behavioral symptoms of autistic disorder. Risperidone, the most rigorously studied of the atypical antipsychotics, is effective for serious behavioral problems in autistic disorder. In this study, risperidone efficacy in reducing irritability and associated behaviors will be assessed in children and adolescents who fulfill DSM-IV and Autism Diagnostic Interview (ADI) criteria. Project Status


Funder National Institutes of Health
Fiscal Year Funding $244.00
Project Number 5M01RR000071-46
Principal Investigator Kolevzon, Alexander
Received ARRA Funding? No
Strategic Plan Question Question 4: Which Treatments And Interventions Will Help? (Interventions)
Strategic Plan Objective Yellow dot: Objective has some degree of funding, but less than the recommended amount. 4LC. Conduct at least one study to evaluate the safety and effectiveness of medications commonly used in the treatment of co-occurring conditions or specific behavioral issues in people with ASD by 2015. IACC Recommended Budget: $10,000,000 over 5 years.
Federal or Private? Federal
Institution Mount Sinai School of Medicine
State/Country New York
Web Link 1 Open label risperidone in children and adolescents with autistic disorder (External web link)
Web Link 2 No URL available.
Web Link 3 No URL available.
History/Related Projects N/A